Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumor, with a 5-year survival rate of approximately 11%. While RT is used to mitigate tumor recurrence in advanced pancreatic cancer, it frequently leads to severe gastrointestinal side effects. An innovative strategy to confront these challenges involves altering the fibroblast-rich tumor microenvironment to enhance its responsiveness to RT.
Our prior research has unveiled a significant upregulation of STAT3 in mouse orthotopic pancreatic tumors post-RT, as compared to untreated tumors, with the induction most pronounced in the fibroblast-rich stromal compartment. Preliminary data suggest that genetic deletion of STAT3 inhibits pancreatic tumor growth. Additionally, STAT3 has been implicated as a central integrator of multiple profibrotic and chronic inflammatory signals in cancer-associated fibroblasts (CAFs). However, whereas STAT3 signaling in PDAC tumor cells has been studied extensively, the significance of CAF-specific STAT3 induction post-RT remains poorly understood. Our studies seek to elucidate the mechanisms by which fibroblast-intrinsic STAT3 contributes to the development of radioresistance, with the ultimate aim of translating these insights into clinical trials for PDAC patients undergoing RT.